½ÃÀ庸°í¼­
»óǰÄÚµå
1671852

½É¹æ¼¼µ¿ ½ÃÀå : À¯Çüº°, Ä¡·á¹ýº°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°

Atrial Fibrillation Market, By Type, By Treatment, By Technology, By End User, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½É¹æ¼¼µ¿ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 264¾ï 3,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö CAGR 7.4%·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 435¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 264¾ï 3,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR 7.40% 2032³â °¡Ä¡ ¿¹Ãø 435¾ï 7,000¸¸ ´Þ·¯
±×¸². ½É¹æ¼¼µ¿ ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2025³â
Atrial Fibrillation Market-IMG1

½É¹æ¼¼µ¿Àº Àü ¼¼°èÀûÀ¸·Î °¡Àå ÈçÇÑ ºÎÁ¤¸ÆÀ̸ç, Áø´Ü »ç·ÊÀÇ À¯º´·üÀÌ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ³ëÀÎ Àα¸ÀÇ Áõ°¡, ½ÉÇ÷°üÁúȯ ¹× »ýȰ½À°üº´ÀÇ À¯º´·ü Áõ°¡, ħ½ÀÀû ½ÉÀå ¼ö¼úÀÇ Áõ°¡, Áø´Ü ¹× Ä¡·á ±â±âÀÇ ±â¼ú ¹ßÀüÀº ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù. ±×·¯³ª ½É¹æ¼¼µ¿ Áø´Ü ¹× Ä¡·á¿¡ µû¸¥ Ç÷Àü»öÀüÁõ À§Çè°ú °³¹ßµµ»ó±¹ÀÇ ½É¹æ¼¼µ¿¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ½É¹æ¼¼µ¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ½É¹æ¼¼µ¿ Ãë¾à ³ëÀÎ Àα¸ÀÇ ±ÞÁõ, ºñ¸¸ ¹× °íÇ÷¾Ð À¯º´·ü Áõ°¡, ¾ËÄÚ¿Ã ¹× ´ã¹è ¼Òºñ Áõ°¡, ħ½ÀÀû ½ÉÀå ¼ö¼úÀÇ Áõ°¡ µîÀÔ´Ï´Ù. ±×·¯³ª ½É¹æ¼¼µ¿ Áø´Ü ¹× Ä¡·á¿¡ µû¸¥ Ç÷Àü»öÀüÁõ À§Çè Áõ°¡, ½ÅÈï±¹ÀÇ ½É¹æ¼¼µ¿¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »õ·Î¿î ÀýÁ¦ ±â¼ú °³¹ßÀÇ ¿¬±¸°³¹ß°ú Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ½ºÅ¸Æ®¾÷ÀÇ ÃâÇöÀº ÇâÈÄ ¸î ³â µ¿¾È Å« ±âȸ¸¦ Á¦°øÇÒ °ÍÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ ½É¹æ¼¼µ¿ ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è ½É¹æ¼¼µ¿ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀ» ȸ»ç ¼Ò°³, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ÁÖ¿ä ¼º°ú, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

ÁÖ¿ä ±â¾÷À¸·Î´Â Pfizer Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, AtriCure, Inc., Sanofi, Bayer AG, Gilead Sciences, Inc., Amgen Inc., Merck & Co., Inc., St. Jude Medical, Inc., Cardiovascular Systems, Inc. µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

½É¹æ¼¼µ¿ ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ½É¹æ¼¼µ¿ ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

  • Á¶»ç ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¿µÇ⠺м®
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° ¹ß¸Å/½ÂÀÎ
  • PEST ºÐ¼®
  • PORTERÀÇ ºÐ¼®
  • ÀμöÇÕº´ ½Ã³ª¸®¿À
  • ¾÷°è µ¿Çâ

Á¦4Àå ¼¼°èÀÇ ½É¹æ¼¼µ¿ ½ÃÀå, À¯Çüº°, 2020-2032³â

  • ¹ßÀÛ¼º ½É¹æ¼¼µ¿
  • Áö¼Ó¼º ½É¹æ¼¼µ¿
  • ¿µ¼Ó¼º ½É¹æ¼¼µ¿

Á¦5Àå ¼¼°èÀÇ ½É¹æ¼¼µ¿ ½ÃÀå, Ä¡·á¹ýº°, 2020-2032³â

  • ¾à¹°¿ä¹ý
  • ºñ¾à¹°¿ä¹ý

Á¦6Àå ¼¼°èÀÇ ½É¹æ¼¼µ¿ ½ÃÀå, ±â¼úº°, 2020-2032³â

  • ¹«¼±Á֯ļö
  • ·¹ÀÌÀú
  • µ¿°á¿ä¹ý
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ½É¹æ¼¼µ¿ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2032³â

  • º´¿ø
  • ½ÉÀå ¼¾ÅÍ
  • ȨÄÉ¾î ¼³Á¤
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ ½É¹æ¼¼µ¿ ½ÃÀå, Áö¿ªº°, 2020-2032³â

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • Pfizer Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Medtronic plc
  • AtriCure, Inc.
  • Sanofi
  • Bayer AG
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Merck & Co., Inc.
  • Jude Medical, Inc.
  • Cardiovascular Systems, Inc.

Á¦10Àå ¾Ö³Î¸®½ºÆ®ÀÇ Ãßõ»çÇ×

  • Wheel of Fortune
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
  • Coherent Opportunity Map

Á¦11Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç ¼Ò°³
ksm 25.04.10

Global Atrial Fibrillation Market is estimated to be valued at US$ 26.43 Bn in 2025 and is expected to reach US$ 43.57 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: US$ 26.43 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 7.40% 2032 Value Projection: US$ 43.57 Bn
Figure. Atrial Fibrillation Market Share (%), By Region 2025
Atrial Fibrillation Market - IMG1

Atrial fibrillation is the most common cardiac arrhythmia globally and the prevalence of diagnosed cases is growing rapidly. Rising geriatric population, increasing incidence of cardiovascular & lifestyle diseases, growth in invasive cardiac procedures, and technological advancements in diagnostic and treatment devices are some of the key factors fueling the growth of this market. However, risk of thromboembolism associated with atrial fibrillation diagnosis and treatment and lack of awareness about atrial fibrillation in developing countries are expected to hamper market growth.

Market Dynamics:

The key drivers propelling the growth of global atrial fibrillation market are rapid growth in geriatric population who are more susceptible to atrial fibrillation, rising prevalence of obesity and hypertension, increasing consumption of alcohol and tobacco, and growing number of invasive cardiac surgeries. However, high risk of thromboembolism associated with atrial fibrillation diagnosis and treatment and lack of awareness about atrial fibrillation in developing countries are projected to hinder the market growth. Growing research on development of novel ablation technologies and emergence of start-up companies offering innovative solutions present significant opportunities in the coming years.

Key Features of the Study:

This report provides in-depth analysis of the global atrial fibrillation market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global atrial fibrillation market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, AtriCure, Inc., Sanofi, Bayer AG, Gilead Sciences, Inc., Amgen Inc., Merck & Co., Inc., St. Jude Medical, Inc., and Cardiovascular Systems, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global atrial fibrillation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global atrial fibrillation market

Market Segmentation

  • Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Paroxysmal Atrial Fibrillation
    • Persistent Atrial Fibrillation
    • Permanent Atrial Fibrillation
  • Treatment Insights (Revenue, USD Bn, 2020 - 2032)
    • Pharmacological Treatments
    • Anticoagulants
    • Antiarrhythmic Drugs
    • Non-Pharmacological Treatments
    • Catheter Ablation
    • Surgical Procedures
    • Implantable Devices
  • Technology Insights (Revenue, USD Bn, 2020 - 2032)
    • Radiofrequency
    • Laser
    • Cryotherapy
    • Others
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals
    • Cardiac Centers
    • Home Care Settings
    • Others
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Pfizer Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Johnson & Johnson
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Medtronic plc
    • AtriCure, Inc.
    • Sanofi
    • Bayer AG
    • Gilead Sciences, Inc.
    • Amgen Inc.
    • Merck & Co., Inc.
    • Jude Medical, Inc.
    • Cardiovascular Systems, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Atrial Fibrillation Market, By Type
    • Global Atrial Fibrillation Market, By Treatment
    • Global Atrial Fibrillation Market, By Technology
    • Global Atrial Fibrillation Market, By End User
    • Global Atrial Fibrillation Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Atrial Fibrillation Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Paroxysmal Atrial Fibrillation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Persistent Atrial Fibrillation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Permanent Atrial Fibrillation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Atrial Fibrillation Market, By Treatment, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pharmacological Treatments
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Anticoagulants
    • Antiarrhythmic Drugs
  • Non-Pharmacological Treatments
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Catheter Ablation
    • Surgical Procedures
    • Implantable Devices

6. Global Atrial Fibrillation Market, By Technology, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Radiofrequency
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Laser
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Cryotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Atrial Fibrillation Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Cardiac Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Home Care Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Atrial Fibrillation Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

9. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim GmbH
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Boston Scientific Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Medtronic plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AtriCure, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
  • Bayer AG
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Merck & Co., Inc.
  • Jude Medical, Inc.
  • Cardiovascular Systems, Inc.

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦